fashion -WSS

fashion

author：leisure time 2025-09-29 20:51:21 - browse：976

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： FDA seeks to regulate lab

hotspot

WSS

Medicaid, Medicare dual

Gut bacteria may contribute to kidney autoimmunity, study finds

How one patient went off dialysis — and others can too

Scientific mystery highlights the blind spots in genomics databases

Study: Black kids more likely to die after surgery than white kids

Paxlovid should be available without a positive Covid test

knowledge

fashion

hotspot

Medicare details structure of new drug price negotiation program

Medicare drug price negotiation program allowed for now

State Dept. review finds Biden bears some blame for Afghanistan failures

Pancreatic cancer is often deadly, but new discoveries are raising hope

Bright Health sells Medicare Advantage business to Molina

People with mental disorders often marry others with same

The high cost of giving birth even with insurance

FDA seeks to regulate lab

BioMarin wins approval for gene therapy to treat hemophilia A

FDA advisers vote against ALS treatment from BrainStorm

hotspot

How one patient went off dialysis — and others can too

Drug companies' payments and gifts affect physicians' prescribing

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Trial using CRISPR to edit HIV out of cells disappoints

Harvard scientists, with Google, unveil the most detailed brain map ever

Hundreds died while taking an arthritis drug, but nobody alerted patients

entertainment

knowledge

hotspot

explore